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INTRODUCTION
The liver is frequently challenged by
metabolic overload, lipid accumulation,
viruses or toxins which induce the for-
mation of radicals and other reactive
oxygen species (ROS) (1,2) and may lead
to cellular damage. Crucial players in the
defense of oxidative stress are antioxi-
dant proteins and enzymes detoxifying
electrophiles and radicals. It is well
known that expression of these cytopro-
tective proteins is controlled by cis-acting
regulatory elements in the promoters of
these genes, the antioxidant responsive
elements (AREs) (3). ARE-driven genes
include glutathione S-transferases (GSTs),
NAD(P)H quinone oxidoreductase 1
(NQO1) and glutamate-cysteine ligase
catalytic subunit (GCLC) (4,5). Further-
more, it has been shown that ARE-driven
gene expression is regulated mainly by
the basic leucine zipper transcription 
factor nuclear factor erythroid 2–related
factor 2 (Nrf2) (6), an important player in
the defense against oxidative stress and a
multiorgan protector in oxidative stress-
related diseases (7). Nrf2 is a member of
the cap “n” collar family of transcription
factors. In its inactive state, Nrf2 is asso-
ciated with the actin-anchored protein
Keap1 and localized in the cytoplasm.
Activation of Nrf2 by electrophiles and
radicals leads to dissociation of Nrf2
from Keap1 and to its translocation into
the nucleus binding in partnership with
other nuclear proteins to ARE sequences
followed by activation of ARE-responsive
genes (7).
Recently, Nrf2 has been shown to play
a crucial role in liver regeneration after
partial hepatectomy, since enhanced ox-
idative stress caused insulin/IGF resist-
ance in Nrf2-deficient hepatocytes,
thereby inhibiting efficient regeneration
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Liver regeneration can be impaired by permanent oxidative stress and activation of nuclear factor erythroid 2–related factor 2
(Nrf2), known to regulate the cellular antioxidant response, and has been shown to improve the process of liver regeneration. A
variety of factors regulate hepatic tissue regeneration, among them augmenter of liver regeneration (ALR), attained great at-
tention as being survival factors for the liver with proproliferative and antiapoptotic properties. Here we determined the Nrf2/ an-
tioxidant response element (ARE) regulated expression of ALR and show ALR as a target gene of Nrf2 in vitro and in vivo. The ALR
promoter comprises an ARE binding site and, therefore, ALR expression can be induced by ARE-activator tertiary butylhydro-
quinone (tBHQ) in hepatoma cells and primary human hepatocytes (PHH). Promoter activity and expression of ALR were en-
hanced after cotransfection of Nrf2 compared with control and dominant negative mutant of Nrf2. Performing partial hepatec-
tomy in livers from Nrf2+/+ mice compared with Nrf2–/– knock-out (KO) mice, we found increased expression of ALR in addition to
known antioxidant ARE-regulated genes. Furthermore, we observed increased ALR expression in hepatitis B virus (HBV) compared
with hepatitis C virus (HCV) positive hepatoma cells and PHH. Recently, it was demonstrated that HBV infection activates Nrf2 and,
now, we add results showing increased ALR expression in liver samples from patients infected with HBV. ALR is regulated by Nrf2,
acts as a liver regeneration and antioxidative protein and, therefore, links oxidative stress to hepatic regeneration to ensure sur-
vival of damaged cells.
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(8). Furthermore, it was found that Nrf2
protects the liver from acute and chronic
toxin-mediated damage and therefore
ameliorates fibrogenesis, which is in part
due to Nrf2-regulated target genes in he-
patocytes (9). Moreover, in vitro and in
vivo studies have shown that hepatitis B
virus (HBV) induces activation of
Nrf2/ARE-regulated genes ensuring pro-
tection of HBV-infected cells against ox-
idative damage and survival of the in-
fected cell (10). Interestingly, infection of
hepatocytes with hepatitis C virus does
not activate Nrf2 and inhibits ARE-
 regulated gene expression. (11).
Liver regeneration is a process regu-
lated by a variety of molecules of which
ALR gains great attention because hepa-
totrophic ALR supports the process of
liver regeneration after partial hepatec-
tomy (12,13), and exerts beneficial effects
in models of hepatic failure (14,15) and
liver fibrosis (16). ALR is a member of the
ALR/Erv1 protein family with a flavin
adenine dinucleotide (FAD)-linked
sulfhydryl oxidase activity and is found
extracellularly as well as within the cyto-
plasm and in the mitochondrial inner-
membrane system (12,17,18). The protein
ALR was identified to augment hepato-
cyte proliferation under conditions in
which the regenerative process has al-
ready been primed and was therefore de-
noted as a comitogen (19,20). The prolif-
eration augmenting the effect of ALR was
attributed to its ability to activate epider-
mal growth factor (EGF) receptor phos-
phorylation and subsequent stimulation
of mitogen-activated protein kinase
(MAPK)/extracellular signal-regulated
kinase (Erk) cascade (21) as well as acti-
vate protein kinase B (Akt/PKB) through
an EGF receptor independent pathway
(22). Furthermore, ALR was described to
have a functional role of a protective and
antiapoptotic/cell survival factor in neu-
roblastoma (23) and hepatoma cells
(24,25) after hydrogen peroxide treatment
(23,25) or irradiation-induced oxidative
stress (24). This was mainly due to the re-
duction of mitochondrial-mediated apo-
ptosis characterized by ameliorated mito-
chondria membrane integrity, reduced
cytochrome c release and enhanced ATP
levels (23–25). In addition, downregula-
tion of ALR expression using antisense
oligonucleotide has demonstrated similar
results in rat hepatocytes (26) and hepa-
toma cells (24) as well as a prosurvival
role of ALR in the maintenance of murine
embryonic stem cell pluripotency (27).
Less is known about the regulation of
ALR expression under conditions of ox-
idative stress. Microarray analyses using
chemopreventive compounds indicate
that Nrf2 regulates expression of cytopro-
tective proteins including ALR (gene:
Gfer) leading to secondary protection
against DNA or protein damage which
enhances cell survival (28,29).
In this study, we analyze whether the
Nrf2 is involved in the regulation of ALR
expression and ALR might therefore be
one of the factors causing cell protective
properties induced by Nrf2. We exam-
ined induction of ALR expression upon
activation of Nrf2 and verified the spe-
cific role of Nrf2/ARE using in vitro Nrf2
overexpression and a Nrf2 –/– mouse
model of partial hepatectomy. Finally, we
could demonstrate that HBV infection,
known to induce Nrf2 activity followed
by enhanced ARE-driven gene expres-
sion, increases ALR expression in vitro
and in human HBV-positive liver tissues.
MATERIALS AND METHODS
Liver Samples and Primary Human
Hepatocytes
Tissue samples from patients undergo-
ing liver surgery at the University Med-
ical Center Regensburg were used, includ-
ing primary hepatocellular carcinoma and
adjacent nontumorous tissue. Primary
human hepatocytes (PHH) were isolated
and cultivated as described recently (31).
Briefly, nonneoplastic tissue samples from
liver resections were obtained from pa-
tients undergoing partial hepatectomy for
metastatic liver tumors of colorectal can-
cer. PHHs were isolated using a modified
two-step ethylene glycol tetraacetic acid
(EGTA)/collagenase perfusion procedure
and plated on collagen coated dishes. Ex-
perimental procedures were performed
according to the guidelines of the charita-
ble state controlled foundation HTCR
(Human Tissue and Cell Research, Re-
gensburg, Germany), with the informed
patient’s consent approved by the local
ethical committee of the University of Re-
gensburg. All experiments involving
human tissues and cells have been carried
out in accordance to “WMA International
Code of Medical Ethics” (30).
Cell Culture
Human hepatoma cell lines HepG2,
HepG2.2.15 (10), Huh7.5 (11) and PLC
(PLC/PRF/5 ATCC CRL-8024) were cul-
tivated in DMEM/1% MEM (Invitrogen/
Life Technologies, Carlsbad, CA, USA),
supplemented with 10% fetal calf serum
(Biochrom, Berlin, Germany), penicillin
(100 units/mL), and streptomycin
(10 μg/mL) and maintained at 37°C, 
5% CO2. HepG2 cells (2 × 10
5) were
seeded and, after 24 h, cells were stimu-
lated with 200 μmol/L tBHQ (tert-
 butylhydrochinone) for 24 h.
Promoter Constructs, Transfections
and Luciferase Reporter Gene Assays
The 5′-flanking region of human ALR
gene (gene ID 2671) residing from –733
to +240 bp (32) was amplified by PCR
and inserted into pGL2-basic plasmid.
HepG2 and Huh-7 cells (2 × 105) were
transiently cotransfected with ALR pro-
moter construct and caNrf2 (constitu-
tively active Nrf2) or dnNrf2 (transdom-
inant negative Nrf2) expression
plasmids (0.5 μg each) (10), using the
siPORT XP-1 method (Ambion/Life
Technologies). Cells were lysed 24 h
after transfection and the luciferase ac-
tivity was determined. To determine the
transfection efficiency, pRL-TKRenilla-
vector was cotransfected and the pro-
moterless vector pGL2-Basic served as
negative control.
Nrf2–/– Mouse Model
Male Nrf2–/– mice in the C57BL/6 back-
ground were provided by M Yamamoto
(University of Tsukuba, Japan) (33). As
controls, age-matched male C57BL/6
mice were obtained from Charles River
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Laboratories (Sulzfeld, Germany). Mice
(8 to 10 wks old) were anesthetized by in-
traperitoneal (IP) injection of ketamine
(100 mg/g bodyweight [bw])/xylazine 
(5 mg/g bw) and subjected to two-thirds
partial hepatectomy as described previ-
ously (34). At different stages after injury,
they were euthanized by CO2 inhalation,
and the remaining livers were harvested.
For each time point studied, at least four
animals were harvested. All experiments
were approved by the local authorities.
Transgenic HBV Mouse Model
The HBV transgenic mouse model
used in this study is based on a 1.3-fold
HBV genome and has been initially de-
scribed elsewhere (35). Liver samples
were derived from 10–12-wk-old trans-
genic mice or the corresponding sex and
age matched wild-type (WT) littermates.
HCV Replicating Cells and 
HBV-Infected Primary Human
Hepatocytes
The plasmids pJFH1/J6 and
pJFH1/J6_GND were described recently
(36). In vitro transcription, electroporation
of HCV RNAs and infection of Huh7.5
cells with HCV were performed as de-
scribed (37). The transfection efficiency
was up to 65%. RNA was isolated 72 h
after electroporation. Primary human he-
patocytes were infected with HepAD38-
derived supernatant as described (38).
Cells were harvested 8 d after infection.
RNA Isolation and cDNA Synthesis
Total RNA was isolated from culti-
vated cells, mouse and human liver tis-
sues using RNeasy kit (Qiagen, Hilden,
Germany). Subsequently, first strand
cDNA was synthesized using 1 μg of
total RNA and virus-reverse transcrip-
tion reaction (Promega, Madison, WI,
USA). For cDNA synthesis of samples
from HCV and HBV experiments, RNA
isolation was performed using TRIzol
(Invitrogen/ Life Technologies) and 5 μg
of total RNA were treated with DNase I
followed by first-strand synthesis using
SupercriptII reverse transcriptase 
(Invitrogen/ Life Technologies).
Quantification of mRNA Expression by
Real-Time PCR
Transcript levels of NQO1, ALR, GSTα1
and 18S ribosomal RNA were quantified
using the RT-PCR (LightCycler, Roche,
Penzberg, Germany). Primers used to am-
plify human ALR were: forward 5′-CAC
AAT GAA GTG AAC CGC AAG-3′, re-
verse 5′-CAC CCA ACT GAG ACA CAA
CAG-3′, mouse ALR: forward 5′-CAC
AGG ATC GGG AAG AAT TG-3′, re-
verse 5′-ATT CCT CGC AGG GGT AAA
AC-3′, human NQO1: forward 5′-GCA
CTG ATC GTA CTG GCT CA-3′, reverse
5′-GAA CAC TCG CTC AAA CCA G-3′,
mouse NQO1: forward 5′-GGC TGC TTG
GAG CAA AAT AG-3′, reverse 5′-TTC
TCT GGC CGA TTC AGA G-3′, mouse
GSTα1: forward 5′-CCG GAA GAT TTG
GAA AAG C-3′, reverse 5′-TTT GGT
GGC GAT GTA GTT GA-3′, 18S rRNA:
forward 5′-GTA ACC CGT TGA ACC
CCA TT-3′, reverse 5′-CCA TCC AAT
CGG TAG TAG CG-3′. The PCR reaction
was evaluated by melting curve analysis.
Western Blot Analysis
Total protein fractions (20 μg/ lane)
were separated by 14% SDS-PAGE under
reducing conditions using 100 mmol/L
DTT. Proteins were transferred onto
polyvinylidene fluoride membranes 
and incubated with anti-ALR (1:440),
anti-β-actin (1:1000) (Santa Cruz Biotech-
nology Inc., Heidelberg, Germany) and
anti-GAPDH (1:1000) (New England Bio-
labs GmbH, Frankfurt, Germany) anti-
bodies, and developed with ECL reac-
tions (Pierce, Rockford, IL, USA).
Immunohistochemistry
Immunostaining was performed as de-
scribed recently (39). Briefly, sections of
paraffin-embedded liver samples were
deparaffinized and incubated with anti-
ALR antibody (0.26 μg/mL) overnight at
4°C. Immunostaining was performed by
incubation with secondary mouse anti-
rabbit antibody (DAKO, Hamburg, Ger-
many) for 1 h and development using
APAAP complex (DAKO) and Fast Red
Chromogen (Roche). Signal intensity of
staining was defined as follows: 0, no
staining; 1 weak staining; 2 when moder-
ate staining; and 3, strong staining.
Statistical Analysis
Significant differences in paired and
nonpaired samples were evaluated using
Wilcoxon signed-rank t test and Mann-
Whitney U test, respectively.
RESULTS
Human ALR Promoter Harbors an
Antioxidant Response Element (ARE)
Previous studies exploring gene ex-
pression profiles induced by chemopre-
ventive compounds such as phenethyl
isothiocyanate (29) and sulforaphane
(28), found enhanced ALR mRNA ex-
pression in WT (Nrf2+/+) mice compared
with KO (Nrf2–/–) mice. This gene induc-
tion primarily occurs via transcription
factor Nrf2 acting on ARE located at the
5′-flanking region of these genes. The ARE
[5′-G(/A)TGAC(/G)NNNGCA(/C)-3′]
motif is a cis-acting element governing
the regulation of multiple antioxidant
genes (3). To identify these potential ARE
motifs in the ALR promoter, we examined
the human ALR (gene ID 2671) genomic
locus and revealed one putative ARE se-
quence in the human ALR promoter. This
ARE sequence [5′-TGACCCGGCA-3′] is
located in the proximal promoter region,
from approximately –27 to –19 bp of the
initial ATG codon. Furthermore, in silico
analysis of the ALR promoter indicated
that potential AREs [5′-TGGCCCCGCT-3′]
also were found from –27 to –19 bp
within the mouse and rat ALR promoter
region.
Nrf2 Induces Promoter Activity and
Expression of ALR
Chemopreventive agents and antioxi-
dants such as tBHQ were shown to stim-
ulate Nrf2, by enabling its release from
Keap 1, followed by its translocation
into the nucleus and heterodimerization
with other transcription factors, such as
Jun and small Maf (6). Therefore, we in-
cubated HepG2 cells and PHH with
tBHQ to activate Nrf2 and analyze if 
activated Nrf2 has an impact on ARE-
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regulated gene expression. In HepG2
cells and PHH we observed enhanced
mRNA expression of ALR and NQO1
after tBHQ treatment, the latter gene
known to be regulated by Nrf2 (Figure
1A). Induced ALR expression after
tBHQ treatment was confirmed for ALR
protein expression by Western blotting
(Figure 1B). Furthermore, to investigate
the involvement of Nrf2 activation in
ARE- regulated ALR expression, we co-
transfected HepG2 and Huh-7 cells with
an ARE harboring luciferase reporter
construct (–733 to +240) of ALR and con-
stitutively active (caNrf2) or transdomi-
nant negative mutant of Nrf2 (dnNrf2)
expression plasmid. The reporter gene
assay demonstrates that expression of
caNrf2 induced and expression of
dnNrf2 slightly reduced ALR promoter
activity (Figure 2A). In addition, quanti-
tative mRNA analysis after transfection
of HepG2 and Huh-7 cells with caNrf2
or dnNrf2 revealed increased or un-
changed expression, respectively, of
ALR and NQO1 (Figure 2B). These re-
sults could be confirmed for ALR pro-
tein expression by Western blotting (Fig-
ure 2C). Taken together, these data
demonstrate that Nrf2 induces expres-
sion of ARE-regulated genes including
ALR in vitro, by activation with antioxi-
dants leading to enhanced promoter ac-
tivity, mRNA and protein expression.
ALR Expression Is Diminished in Livers
of Hepatectomized Nrf2–/– Mice
Recently, Nrf2 was demonstrated to
play an essential role in liver regenera-
tion, since Nrf2-deficient mice show sig-
nificantly delayed liver regeneration
after partial hepatectomy (8). To investi-
gate whether ALR expression is depen-
dent on Nrf2 activation in vivo under cir-
cumstance of liver regeneration, we used
a two-thirds-partial-hepatectomy mouse
model applied to Nrf2 WT and Nrf2–/–
mice. Expression of NQO1 and GSTα
mRNA, both genes being regulated by
Nrf2, is reduced significantly in Nrf2–/–
compared with Nrf2 WT mice at 0, 6, 10,
24 h and 0, 6, 10 h after hepatectomy, re-
spectively (Figures 3A, B). ALR mRNA ex-
pression is significantly abolished at 0 and
10 h after hepatectomy in Nrf2–/– com-
pared with Nrf2 WT mice (Figures 3C, D).
This finding could be confirmed for ALR
protein expression by Western blotting
(see Figure 3D) with reduced ALR levels
in Nrf2–/– mice compared with Nrf2 WT
at 0 and 10 h after hepatectomy. These
data show that activation of Nrf2 is
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Figure 1. Specific Nrf2 inducer activates ALR expression. (A) mRNA expression of NQO1
and ALR was analyzed after stimulation with tBHQ (200 μmol/L, 24 h) in HepG2 and PHH
by qRT-PCR. Untreated cells served as control and 18S ribosomal RNA expression was de-
termined for normalization (two independent experiments in triplicates, mean ± SD). 
(B) ALR protein expression in cellular lysates of HepG2 cells stimulated without or with
tBHQ (200 μmol/L, 24 h) was analyzed by Western blotting followed by densitometry. *P <
0.05 differs from corresponding control.
Figure 2. Nrf2 expression induces ALR expression. (A) For reporter-gene assay HepG2 and
Huh-7 cells were cotransfected with luciferase-reporter construct harboring ALR promoter
(–733 to +240) with putative ARE sequence and caNrf2 or dnNrf2 expression plasmids (all
0.5 μg each). Cotransfection with pcDNA3 vector served as control and was set 1 (three
independent experiments in triplicates, mean ± SEM). (B) For mRNA expression analysis,
HepG2 and Huh-7 cells were transfected with caNrf2 or dnNrf2 expression plasmid (1 μg,
24 h) and mRNA expression of ALR as well as NQO1 were analyzed by quantitative RT-
PCR. Transfection with pcDNA3 vector served as control and was set 1. 18S ribosomal RNA
expression was determined for normalization (two independent experiments in triplicates,
mean ± SEM). (C) Western blot analysis of cellular lysates of HepG2 cells transfected with
caNrf2 or dnNrf2 expression plasmids was performed followed by densitometric analysis of
21- and 23-kDa ALR band. *P < 0.05 differs from corresponding control.
mandatory for expression of ARE-
 regulated genes including, at least in
part, ALR, under normal conditions and
circumstances of liver regeneration.
ALR Expression Is Enhanced in 
HBV-Positive Cells
Activation of Nrf2 followed by expres-
sion of ARE-regulated genes was not
only shown for chemopreventive and an-
tioxidant agents, but also reported to be
mediated by hepatitis B virus (HBV) (10),
while hepatitis C virus (HCV) inhibits
Nrf2 activation (11). Therefore, we ana-
lyzed the potential impact of HBV and
HCV infection on ALR expression in vitro
and in vivo. Expression of ALR mRNA is
increased in cells expressing HBV spe-
cific proteins (after infection) as demon-
strated by qRT-PCR analysis of HBV-
 positive stable cell lines HepG2.2.15 and
PLC compared with HBV-negative
HepG2 cells and PHH (Figure 4A). Speci-
ficity of HBV-mediated activation of
NQO1 expression in HBV-positive stable
cell lines was shown previously (10).
Furthermore, ALR mRNA expression is
significantly enhanced 8 d post infection
in HBV-infected versus noninfected PHH
(Figure 4B), while no difference in ALR
expression was observed in HCV-positive
(replicating Huh7.5 cells) compared with
HCV-negative cells (replication-deficient
Huh7.5 cells). Additionally, ALR protein
expression is increased in HBV-positive
liver tissue homogenates from HBV
transgenic mice compared with WT mice
demonstrated by Western blot analysis
(Figure 4C).
Moreover, analysis of liver tissue sam-
ples from patients with HCV and HBV
infection for ALR mRNA expression by
RT-qPCR reveals enhanced ALR expres-
sion in HBV-positive versus HCV-positive
liver tissues (Figure 5A). Liver samples
were nontumorous tissues with signs of
cirrhosis, fibrosis and inflammation. Fur-
thermore, we performed immunohisto-
chemical analysis of hepatocellular carci-
noma (HCC) samples and nontumorous
liver samples adjacent to HCC and found
ALR expression solely in hepatocytes
and cholangiocytes as described earlier
(Figure 5C) (48). ALR immunoreactivity
was analyzed using an intensity score
and revealed enhanced ALR protein ex-
pression in nontumorous liver tissue
from patients with HBV infection com-
pared with liver tissue from patients
without HBV infection or alcohol intoxi-
cation (Figures 5B, C). Interestingly, we
could not find a correlation of ALR ex-
pression in the corresponding adjacent
HCC samples.
DISCUSSION
In this study, for the first time, we
show that expression of protective and
antiapoptotic protein ALR is regulated
by activation of the antioxidant
Nrf2/ARE system. We demonstrate that
overexpression of constitutive active
Nrf2 resulted in enhanced expression of
an ARE specific gene, NQO1, as well as
ALR (Figure 2). Furthermore, a typical
inducer of ARE driven genes, tBHQ, con-
firmed these observations by increasing
mRNA and protein expression of NQO1
and ALR (Figure 1). It is widely accepted
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Figure 3. Reduced expression of ARE-regulated genes in Nrf2–/– mice after partial hepate-
ctomy. A two-thirds partial hepatectomy using Nrf2 WT or Nrf2–/– mice was performed in-
ducing liver regeneration. Liver tissue samples were taken at indicated time points after
surgery. (A–C) mRNA expression of NQO1 (A) and GST (B), and ALR (C) was determined
by quantitative RT-PCR analysis. 18S ribosomal RNA expression was measured for normal-
ization (four independent experiments, mean ± SEM). (D) Western blot analysis of liver tis-
sue homogenates from Nrf2 WT and Nrf2–/– mice after two-thirds partial hepatectomy was
performed followed by densitometric analysis of 21- and 23-kDa ALR band at the indi-
cated time points (one of four mice are presented). *P < 0,05 Nrf2 WT differs from Nrf2–/–;
#P < 0.05 differs from 0 h.
that enhanced oxidative stress is associ-
ated with increased Nrf2 activity and, as
a consequence, upregulated antioxidant
gene expression. Within this study we
present some evidence that ALR, in addi-
tion to known antioxidant genes, is a
protein regulated in response to Nrf2 ac-
tivation to address cellular oxidative
stress. This is underlined by observations
that ALR reduces cell damage and apo-
ptosis upon oxidative stress (13,24) and
also improves renal function by reducing
the extent of tubular injury in a renal
 ischemia/reperfusion model in which in-
jury is known to be mediated by oxida-
tive stress (40).
Performing an ALR promoter analysis,
we found the presence of a cis-acting reg-
ulatory element ARE in the 5′-flanking
region of ALR gene. Interestingly, it was
reported that the ALR 5′-flanking region
contains a core promoter (–66/ –1 bp)
proximal of the ALR start codon, which
showed an initiatorlike element with
three tandem repeats (41). This promoter
sequence, able to activate the ALR pro-
moter, harbors the so far unrecognized
ARE element (–27/–19 bp) which is lo-
cated between the initiatorlike element
and the initial start codon of the ALR
gene. It would be of interest if these two
elements act in a combinatorial manner
to regulate ALR expression and if this
might explain different expression pro-
files. Furthermore, the ALR promoter re-
gion revealed putative binding sites for
AP1/AP4 (42), SP1 and HNF-4α (43), all
of them located upstream of –49 bp from
the transcriptional start site of the ALR
gene. Recently, we found additional pu-
tative binding sites in an intronic ALR
promoter and could confirm binding of
Foxa2 (HNF-3β) to this ALR promoter re-
gion (+276/+282 bp) (32). Subsequently,
ALR promoter was activated and ALR
expression increased, which could be
amplified by IL-6 treatment (32). There-
fore, Foxa2 or IL-6, in addition to Nrf2,
might have an impact on expression of
ALR after partial hepatectomy in mice
(Figure 3C), since it has been reported
that Foxa2 is upregulated consistently
during liver regeneration (44) and IL-6
was shown to be slightly induced after
injury in Nrf2 WT and KO mice (8). Fur-
thermore, this might explain the not fully
blunted ALR expression in the Nrf2 KO
model at 6 and 10 h post hepatectomy
(Figure 3C). In addition, the observed in-
crease in ALR expression in HCC sam-
ples despite of different underlying etiol-
ogy (Figure 5B), might only in part be
dependent on Nrf2, but also on Foxa2 ac-
tivity. Foxa2 was reported to be upregu-
lated in livers from patients with HCC,
suggesting a potential role in tumorigen-
esis (45).
The roles of Nrf2 in toxin detoxification
and cancer prevention have been well es-
tablished, and a novel function of Nrf2 in
liver regeneration was demonstrated re-
cently. Deficiency in this transcription fac-
tor resulted in enhanced oxidative stress in
the normal and particularly in the injured
liver due to reduced expression of ROS-
detoxifying enzymes (8). This was con-
firmed in our study and, in addition, we
found diminished ALR expression levels
in normal and hepatectomized livers (Fig-
ure 3). Furthermore, under pathological
conditions, besides hepatocyte prolifera-
tion, enhanced hepatocyte apoptosis can
occur after hepatectomy (46). Using the
Nrf2 KO model, the number of apoptotic
cells after hepatectomy increased several-
fold compared with WT controls (8). This
indicates enhanced ROS- mediated apopto-
sis and that Nrf2 regulated gene expres-
sion can abate this process. ALR is one of
these Nrf2 regulated genes able to reduce
apoptosis, which is supported by a recent
report demonstrating that ALR adminis-
tration induces antiapoptotic gene expres-
sion,  inhibits hepatocyte apoptosis and re-
duces ROS-induced cell damage in a rat
model of partial hepatectomy (13). En-
hanced oxidative stress in the Nrf2 KO
model is responsible for an impairment of
insulin/IGF signaling and subsequent in-
hibition of PI3K-Akt pathway, explaining
increased apoptosis and reduced liver re-
generation (8). Therefore, ALR supports
liver regeneration by reducing intracellu-
lar-generated ROS, enabling activation of
survival and proliferation signaling
through PI3K-Akt pathway by growth fac-
tors or even by ALR itself (22).
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Figure 4. HBV infection, known to induce Nrf2 activity, enhances ALR expression. (A) ALR
mRNA expression in HBV-positive hepatoma cell lines (HepG2.2.15, PLC) compared with
noninfected PHH and HepG2 cells was analyzed by qRT-PCR. 18S ribosomal RNA expres-
sion was used for normalization. *P < 0.05 differs from PHH and HepG2. (B) Huh7.5 cells
were transfected with HCV replicon pJFH/J6 and replication-deficient construct
pJFH/J6_GND (served as control) as well as PHHs were infected with HBV or not. HCV
replicating cells were analyzed 72 h after electroporation, the HBV-infected PHH 8 d after
infection for ALR mRNA expression. 18S ribosomal RNA expression was used for normaliza-
tion (mean ± SEM). #P < 0.05 differs from noninfected PHH. C) Western blot analysis of liver
tissue homogenates derived from HBV-transgenic mice or the corresponding WT animals
were performed followed by densitometric analysis of 21- and 23-kDa ALR band.
In a previous report, we have shown
that HBV induces a strong activation of a
variety of cytoprotective genes that are
Nrf2/ARE-regulated (10). In line with
this observation, we found ALR expres-
sion induced in HBV-infected, but not in
HCV-infected, cells in vitro and in vivo
(Figures 4, 5), which is in agreement with
some recent findings reporting a HCV-
dependent inhibition of Nrf2/ARE-
 regulated genes (11). In addition, it was
reported that Nrf2 protects from toxin-
 induced liver injury and fibrosis (9),
which seems to be contradictory to
chronic HBV infection as a causative fac-
tor for liver fibrosis, cirrhosis or HCC.
Permanent activation of the inflamma-
tory process after chronic infection is
characterized by increased ROS levels.
Induction of Nrf2/ARE- regulated genes,
such as ALR, by HBV protects HBV-
 positive cells and thereby ensures viral
replication. It would be intriguing to
know how a loss in Nrf2 activation may
affect HBV- associated pathogenesis in
liver diseases. Furthermore, in HCCs,
overexpression of ARE-regulated genes
was found to be advantageous to these
tumors (47). Enhanced ALR expression
in hepatic tumors was reported earlier
(39,48), but a correlation of increased ex-
pression of ALR with HBV-associated
HCCs could not be confirmed. The over-
expression of many proteins, which func-
tion as antioxidants and detoxifying en-
zymes, is likely to protect the tumor from
elimination by mechanisms that are
based on increased electrophiles or radi-
cals and therefore count for chemoresis-
tance and tumor promotion (47).
CONCLUSION
In summary, we present evidence that
ALR is one of the ARE-regulated genes,
which can be induced by Nrf2 activation.
Therefore, ALR expression as a conse-
quence of a functional ARE/Nrf2 system
accounts for efficient liver regeneration
and protection of cells from oxidative
stress, for example, after HBV infection.
Furthermore, based on the crucial role of
Nrf2 in the protection of hepatocytes from
acetaminophen (7), ethanol (49) and bile
acid (50) toxicity, we hypothesize a benefi-
cial effect of ALR on liver damage caused
by these noxious effects and postulate a
functional role of ALR in the pathogenesis
of steatosis, NASH and fibrosis.
ACKNOWLEDGMENTS
The authors are grateful to Friederike
Schrenk, Elke Gerstl and Renate Lange,
Department of Pediatrics and Juvenile
Medicine, University of Regensburg Hos-
pital, Germany, for their excellent techni-
cal assistance. This work was supported
by the Excellence Cluster REBIRTH for 
A Vogel, the Medical Faculty of the Uni-
versity of Regensburg ReForM-C for 
TS Weiss and the German Federal Min-
istry of Education and Research (BMBF)
Virtual Liver Network grant FKZ 0315753
to TS Weiss.
R E S E A R C H  A R T I C L E
M O L  M E D  1 9 : 2 3 7 - 2 4 4 ,  2 0 1 3  |  D A Y O U B E T  A L .  |  2 4 3
Figure 5. Increased ALR expression in HBV-positive liver tissue. (A) ALR mRNA expression in
liver tissue samples from patients with positive HCV (n = 10) or HBV (n = 10) infection was
analyzed by quantitative RT-PCR analysis. 18S ribosomal RNA expression was measured for
normalization, *P < 0.05. (B) Sections of liver tissue samples from patients with HCC and
nontumorous adjacent liver tissue were analyzed for ALR immunoreactivity. Etiology of he-
patocellular carcinoma (HCC) samples: without (w/o) HBV infection and no alcohol n =
12, alcohol n = 14, HBV infection n = 7; nontumorous liver tissue adjacent to HCC: without
(w/o) HBV infection and no alcohol n = 5, alcohol n = 4, HBV infection n = 8. Intensity of
anti-ALR staining was categorized from 0 to 3 (values are declared as mean ± SEM). *P <
0.05 HBV differs from w/o HBV, alc. (C) ALR protein immunoreactivity in nontumorous liver
tissue sections adjacent to HCC as described in (B), (i) without (w/o) HBV infection and
no alcohol, (ii) alcohol intoxication and iii) HBV infection. ALR expression was detected in
the majority of hepatocytes (i–iii) and in cholangiocytes (ii), but was negative in non-
parenchymal liver cells (48). (i–iii, magnification 250×).
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